標(biāo)題: Titlebook: Breast Cancer Chemosensitivity; Dihua Yu,Mien-Chie Hung Book 2007 The Editor(s) (if applicable) and The Author(s), under exclusive license [打印本頁] 作者: 小費 時間: 2025-3-21 18:41
書目名稱Breast Cancer Chemosensitivity影響因子(影響力)
書目名稱Breast Cancer Chemosensitivity影響因子(影響力)學(xué)科排名
書目名稱Breast Cancer Chemosensitivity網(wǎng)絡(luò)公開度
書目名稱Breast Cancer Chemosensitivity網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Breast Cancer Chemosensitivity被引頻次
書目名稱Breast Cancer Chemosensitivity被引頻次學(xué)科排名
書目名稱Breast Cancer Chemosensitivity年度引用
書目名稱Breast Cancer Chemosensitivity年度引用學(xué)科排名
書目名稱Breast Cancer Chemosensitivity讀者反饋
書目名稱Breast Cancer Chemosensitivity讀者反饋學(xué)科排名
作者: travail 時間: 2025-3-21 20:19 作者: 語言學(xué) 時間: 2025-3-22 02:08
Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance,wever, attempts to modulate the activities of these transporters using reversal agents have met with limited success. Future studies should focus on better understanding of the upregulation mechanisms of ABC transporter genes in breast cancers, and of the pharmacologic mechanisms of transporter-reve作者: sterilization 時間: 2025-3-22 06:50
Therapy-Induced Apoptosis in Primary Tumors,models, the evidence that apoptosis does or does not mediate the effects of current front line therapies in patients, and the new strategies that are emerging that are designed to more directly target apoptotic pathways.作者: Charade 時間: 2025-3-22 11:29
,Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?,tive measure of response..This review describes the mechanisms of resistance to commonly used systemic therapies for the treatment of breast cancer, with particular respect to the role of the cell cycle. The mechanisms and effects of the deregulation of cyclin E in breast cancer are reviewed and nov作者: negotiable 時間: 2025-3-22 14:04
Integrin-Mediated Adhesion: Tipping the Balance between Chemosensitivity and Chemoresistance,ecent evidence suggests that integrin-mediated adhesion to the ECM may undermine the response of tumors to chemotherapeutic agents. Integrins have been shown to be readily accessible drug targets and are therefore attractive potential targets for combined modality chemotherapy.作者: ambivalence 時間: 2025-3-22 18:54
Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story,the activity of a critical survival factor Akt and/or upregulating the activities of a pro-apoptotic kinase p38 and a protein phosphatase PP2A, etc. This review summarizes these progresses and proposes a plausible feed-forward model for E1A-mediated chemosensitization in human breast cancer cells.作者: Erythropoietin 時間: 2025-3-22 22:15 作者: obstruct 時間: 2025-3-23 02:49
Public Sphere in the Digital Age,wever, attempts to modulate the activities of these transporters using reversal agents have met with limited success. Future studies should focus on better understanding of the upregulation mechanisms of ABC transporter genes in breast cancers, and of the pharmacologic mechanisms of transporter-reve作者: 北京人起源 時間: 2025-3-23 07:30 作者: Immunotherapy 時間: 2025-3-23 12:35
Kuppusamy Singaravelloo,Kamal Salihtive measure of response..This review describes the mechanisms of resistance to commonly used systemic therapies for the treatment of breast cancer, with particular respect to the role of the cell cycle. The mechanisms and effects of the deregulation of cyclin E in breast cancer are reviewed and nov作者: Embolic-Stroke 時間: 2025-3-23 15:22 作者: 治愈 時間: 2025-3-23 22:01
,Lowry and ‘the great figure of Authority’,the activity of a critical survival factor Akt and/or upregulating the activities of a pro-apoptotic kinase p38 and a protein phosphatase PP2A, etc. This review summarizes these progresses and proposes a plausible feed-forward model for E1A-mediated chemosensitization in human breast cancer cells.作者: CRACK 時間: 2025-3-24 01:16
0065-2598 rapy to get a jump-start on critical issues in breast cancer.In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem Breast Cancer Chemosensitivity moves作者: 不發(fā)音 時間: 2025-3-24 04:40 作者: fidelity 時間: 2025-3-24 06:30 作者: 防止 時間: 2025-3-24 13:13
https://doi.org/10.1007/978-981-33-4137-1 in breast cancer chemosensitivity. We discuss the known signaling pathways downstream of p53 or BRCA1 that contribute to their modulation of therapeutic responses, and we discuss the implications of p53 or BRCA1 mutation in therapeutic design.作者: Anthropoid 時間: 2025-3-24 16:03 作者: Seizure 時間: 2025-3-24 19:40
The Novellas and the Short Stories,omeostasis and receptor coregulator proteins. Additionally, the role of nonclassical ERα signaling through growth factor receptors and the subsequent downstream-initiated signaling, and the role of the progesterone receptors will be discussed.作者: Alienated 時間: 2025-3-24 23:41
p53, BRCA1 and Breast Cancer Chemoresistance, in breast cancer chemosensitivity. We discuss the known signaling pathways downstream of p53 or BRCA1 that contribute to their modulation of therapeutic responses, and we discuss the implications of p53 or BRCA1 mutation in therapeutic design.作者: ureter 時間: 2025-3-25 05:29 作者: expository 時間: 2025-3-25 10:55
Estrogen Receptors in Resistance to Hormone Therapy,omeostasis and receptor coregulator proteins. Additionally, the role of nonclassical ERα signaling through growth factor receptors and the subsequent downstream-initiated signaling, and the role of the progesterone receptors will be discussed.作者: Indigence 時間: 2025-3-25 11:48 作者: geometrician 時間: 2025-3-25 17:24
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance,ors even as a monomer..–. The binding of ErbB2 to other ErbB receptors results in increased signaling potency of the dimerized receptors through several means, including increased ligand affinity, increased coupling efficiency to signaling molecules, and decreased rate of receptor internalization..–.作者: 辮子帶來幫助 時間: 2025-3-25 22:11
Book 2007emotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment..作者: 滔滔不絕地說 時間: 2025-3-26 02:20 作者: 感激小女 時間: 2025-3-26 05:55
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer,rld in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease. To offer more effective and less toxic treatment, selecting therapi作者: overture 時間: 2025-3-26 12:22 作者: 使人煩燥 時間: 2025-3-26 15:13
Therapy-Induced Apoptosis in Primary Tumors,d by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the precl作者: lactic 時間: 2025-3-26 19:54 作者: 礦石 時間: 2025-3-26 21:19 作者: 紳士 時間: 2025-3-27 01:49
Integrin-Mediated Adhesion: Tipping the Balance between Chemosensitivity and Chemoresistance,mor progression and metastasis. Integrins cooperate with growth factor receptors to control many cellular functions including proliferation and cell survival. Integrin-mediated adhesion regulates many of the cell cycle checkpoints including activation of cyclin D/cdk4/6 complexes, expression of cycl作者: sorbitol 時間: 2025-3-27 07:48
Insulin-Like Growth Factors and Breast Cancer Therapy,s or may have utility in combination with other agents. Population, preclinical, and basic data suggest the insulin-like growth factor (IGF) system functions to maintain the malignant phenotype in breast cancer. Since the IGFs act via transmembrane tyrosine kinase receptors, targeting of the key rec作者: 失眠癥 時間: 2025-3-27 10:39 作者: 宿醉 時間: 2025-3-27 13:41
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance,. ErbB2 is a receptor tyrosine kinase with intrinsic tyrosine kinase activity. The mammalian EGFR family comprises four receptors (EGFR, ErbB2, ErbB3, and ErbB4), which are derived from a series of gene duplications early in vertebrate evolution and are 40%–45% identical.. ErbB2 is the only EGFR fam作者: Seminar 時間: 2025-3-27 18:17
Estrogen Receptors in Resistance to Hormone Therapy,unctional receptors. Thus, the ER is a major target for current and developing therapies. Although most ER-positive tumors initially respond to hormonal therapies such as tamoxifen, many tumors will eventually become resistant to tamoxifen induced growth inhibition. This chapter will discuss molecul作者: 課程 時間: 2025-3-28 01:50 作者: 神秘 時間: 2025-3-28 03:56
Breast Cancer Chemosensitivity978-0-387-74039-3Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: 終端 時間: 2025-3-28 10:08 作者: Manifest 時間: 2025-3-28 11:05 作者: 誤傳 時間: 2025-3-28 17:50
An Early Introduction to Brutal Politicsrld in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease. To offer more effective and less toxic treatment, selecting therapi作者: 娘娘腔 時間: 2025-3-28 19:45 作者: VALID 時間: 2025-3-29 01:27
Education: The Past and the Future,d by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the precl作者: assail 時間: 2025-3-29 03:53 作者: Conclave 時間: 2025-3-29 08:38 作者: deadlock 時間: 2025-3-29 15:02
https://doi.org/10.1007/978-981-33-4137-1mor progression and metastasis. Integrins cooperate with growth factor receptors to control many cellular functions including proliferation and cell survival. Integrin-mediated adhesion regulates many of the cell cycle checkpoints including activation of cyclin D/cdk4/6 complexes, expression of cycl作者: Eosinophils 時間: 2025-3-29 16:25 作者: 極大痛苦 時間: 2025-3-29 21:45 作者: febrile 時間: 2025-3-30 01:26
https://doi.org/10.1007/978-1-349-19973-0. ErbB2 is a receptor tyrosine kinase with intrinsic tyrosine kinase activity. The mammalian EGFR family comprises four receptors (EGFR, ErbB2, ErbB3, and ErbB4), which are derived from a series of gene duplications early in vertebrate evolution and are 40%–45% identical.. ErbB2 is the only EGFR fam作者: Meager 時間: 2025-3-30 08:07 作者: Bumptious 時間: 2025-3-30 09:20 作者: 賄賂 時間: 2025-3-30 15:19
Dihua Yu,Mien-Chie HungA useful reference to some of the most important aspects of systemic therapy resistance.Allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer
